Skip to main content
SpringerLink
Log in

Adjuvant treatment strategies for pancreatic cancer

  • Review Article
  • Published:
Journal of Gastrointestinal Surgery

Abstract

Pancreatic cancer is a difficult and unsolved surgical problem. It remains one of the top five causes of cancer-related deaths and has the lowest 5-year survival of any cancer, largely due to late diagnosis, low resection rates, and local recurrence. Clinical trials examining the optimal timing and delivery of adjuvant therapies for pancreatic cancer have yielded controversial results. Although most experts agree that the addition of chemotherapy has survival benefit in patients with resectable pancreatic cancer, there is no consensus regarding the optimal therapeutic agents, timing (neoadjuvant versus adjuvant), and the addition of radiation therapy to the treatment regimen. Multiple phase III trials are in progress in efforts to examine these issues. Additionally, exciting progress has been made with novel chemotherapeutic combinations, and alternative treatment modalities including interferon-α, immunotherapy, and pancreatic cancer stem cells. Given the high failure pattern after surgical resection, with more than half of patients developing locoregional recurrence, all patients undergoing pancreaticoduodenectomy are candidates for adjuvant therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10–30.

    Article  PubMed  Google Scholar 

  2. Riela A, Zinsmeister AR, Melton LJ 3rd, Weiland LH. Increasing incidence of pancreatic cancer among women in Olmsted County, Minnesota, 1940 through 1988. Mayo Clin Proc 1992;67:839–845.

    PubMed  CAS  Google Scholar 

  3. Niederhuber JE, Brennen MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. Cancer 1995;76:1671–1677.

    Article  PubMed  CAS  Google Scholar 

  4. Lowenfels AB, Maisonneuve P, DiMagno EP, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 1997;89:442–446.

    Article  PubMed  CAS  Google Scholar 

  5. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993;328:1433–1437.

    Article  PubMed  CAS  Google Scholar 

  6. Ghadirian P, Boyle P, Simard A, et al. Reported family aggregation of pancreatic cancer within a population-based control study in the Francophone community in Montreal, Canada. Int J Pancreatol 1991;10:183–196.

    PubMed  CAS  Google Scholar 

  7. Maringhini A, Ciambra M, Raimondo M, et al. Clinical presentation and ultrasonography in the diagnosis of pancreatic cancer. Pancreas 1993;8:146–150.

    Article  PubMed  CAS  Google Scholar 

  8. Weirsema MJ, Norton ID, Clain JE. Role of EUS in the evaluation of pancreatic adenocarcinoma. Gastrointest Endosc 2000;52:578.

    Article  Google Scholar 

  9. Mertz HR, Sechopoulos P, Delbeke D, Leach SD. EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma. Gastrointest Endosc 2000;52:367–371.

    Article  PubMed  CAS  Google Scholar 

  10. Tierney WM, Francis IR, Eckhauser F, et al. The accuracy of EUS and helical CT in the assessment of vascular invasion by periampullary malignancy. Gastrointest Endosc 2001;53:182–188.

    Article  PubMed  CAS  Google Scholar 

  11. Varghese JC, Farrell MA, Courtney G, et al. Role of MR cholangiopancreatograpy in patients with failed or inadequate ERCP. AJR Am J Roentgenol 1999;173:1527–1533.

    PubMed  CAS  Google Scholar 

  12. Steinberg W. The clinical utility of the CA19-9 tumor-associated antigen. Am J Gastroenterol 1990;85:350–355.

    PubMed  CAS  Google Scholar 

  13. Pleskow DK, Berher HJ, Gyves J, et al. Evaluation of a serological marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 1989;110:704–709.

    PubMed  CAS  Google Scholar 

  14. Goggins M. Molecular markers of early pancreatic cancer. J Clin Oncol 2005;23:4524–4531.

    Article  PubMed  CAS  Google Scholar 

  15. Cao D, Hustinx SR, Sui G, et al. Identification of novel highly expressed genes in pancreatic ductal adenocarcinoma through a bioinformatics analysis of expressed sequence tags. Cancer Biol Ther 2005;3:1081–1089.

    Google Scholar 

  16. Koopman J, White CN, Zhang Z, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: MIC-1 vs. CA19-9. Presented at Gastroenterology Digestive Diseases Week, Chicago, IL, May 14–19, 2005.

  17. Koopman J, Buckhaults P, Brown DA, et al. Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 2004;10:2386–2392.

    Article  Google Scholar 

  18. Saldinger PF, Reilly M, Reynolds K, et al. Is CT angiography sufficient for prediction of resectability of periampullary neoplasms? J Gastrointest Surg 2000;4:233–237.

    Article  PubMed  CAS  Google Scholar 

  19. Tseng JF, Raut CP, Lee E, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004;8:935–949.

    Article  PubMed  Google Scholar 

  20. Gastrointestinal Tumor Study Group. A multi-institutional comparative trial of radiation therapy alone and in combination with 5-FU for locally unresectable pancreatic carcinoma. Ann Surg 1979;189:205–208.

    Google Scholar 

  21. Roldan GE, Gunderson LL, Nagorney DM, et al. External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. Cancer 1988;61:1110–1116.

    Article  PubMed  CAS  Google Scholar 

  22. Burris HA III, Moore MJ, Andersen MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403–2413.

    PubMed  CAS  Google Scholar 

  23. Tempero M, Plunkett W, Ruiz Van Haperen V, et al. Randomized phase II comparison of dose-intense gemcitabine: thirty minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 2003;21:3402–3408.

    Article  PubMed  CAS  Google Scholar 

  24. Stathopoulos GP, Syrigos K, Polyzos G, et al. Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an Intergroup, multicenter, phase II study. Ann Oncol 2004;15:97–104.

    Google Scholar 

  25. Louvet C, Andre G, Lledo P, et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol 2002;20:1512–1518.

    Article  PubMed  CAS  Google Scholar 

  26. Brembeck FH, Schoppmeyer K, Leupold U, et al. A phase II pilot trial of 13-cis retinoic acid and interferon-alpha in patients with advanced pancreatic carcinoma. Cancer 1998;83:2317–2323.

    Article  PubMed  CAS  Google Scholar 

  27. Yeo CJ, Cameron JL, Lilemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg 1995;221:721–723.

    Article  PubMed  CAS  Google Scholar 

  28. Birkmeyer JD, Warshaw AL, Finlayson SRG, et al. Relationship between hospital volume and late survival after pancreaticoduodenectomy. Surgery 199;126:178–183.

  29. Lim JE, Chien MW, Earle CC. Prognostic factors following curative resection for pancreatic adenocarcinoma: a population-based, linked database analysis of 396 patients. Ann Surg 2003;237:74–85.

    Article  PubMed  Google Scholar 

  30. Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985–1995, using the National Cancer Database. J Am Coll Surg 1999;189:1–7.

    Article  PubMed  CAS  Google Scholar 

  31. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899–903.

    PubMed  CAS  Google Scholar 

  32. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 1999;230:776–782.

    Article  PubMed  CAS  Google Scholar 

  33. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomized controlled trial. Lancet 2001;358:1576–1585.

    Article  PubMed  CAS  Google Scholar 

  34. Yeo CJ, Abrams RA, Grochow LB, et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single institution experience. Ann Surg 1997;225:621–633.

    Article  PubMed  CAS  Google Scholar 

  35. A phase III study of pre and post chemoradiation 5-FU vs pre and post chemoradiation gemcitabine for postoperative adjuvant treatment of resected pancreatic adenocarcinoma. The Radiation Therapy Oncology Group (Website). Available at: http://www.rtog.org/members/protocols/97-04/97-04.pdf. Accessed July 10, 2005.

  36. Bakkevold KE, Arnesjo B, Dahl O, et al. Adjuvant combination chemotherapy (AMF) following radical resection of carcinoma of the pancreas and papilla of Vater—results of a controlled, prospective, randomized multicentre study. Eur J Cancer 1993;29A:698–703.

    Article  PubMed  CAS  Google Scholar 

  37. Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002;95:1685–1695.

    Article  PubMed  Google Scholar 

  38. Oettle H, Arning M, Langrehr J, et al. A randomized study of gemcitabine versus observation as adjuvant treatment for pancreatic cancer: results of an interim safety analysis (abstract). Proc Am Soc Clin Oncol 2001;20:46.

    Google Scholar 

  39. European Study Group for Pancreatic Cancer Trial 3. Adjuvant chemotherapies in operable pancreatic cancer. Available at: http://www.liv.ac.uk/surgery/Espac5.html. Accessed October 1, 2005.

  40. Bosset JF, Pavy JJ, Gillet M, et al. Conventional external irradiation alone as adjuvant treatment in resectable pancreatic cancer: results of a prospective study. Radiother Oncol 1992;24:191–194.

    Article  PubMed  CAS  Google Scholar 

  41. Hosotani R, Kogire M, Arii S, et al. Results of pancreatectomy with radiation therapy for pancreatic cancer. Hepatogastroenterology 1997;44:1528–1535.

    PubMed  CAS  Google Scholar 

  42. Breslin TM, Hess KR, Harbison DB, et al. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Ann Surg Oncol 2001;8:123–132.

    Article  PubMed  CAS  Google Scholar 

  43. Mehta VK, Fisher G, Ford JA, et al. Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas. J Gastrointest Surg 2001;5:27–35.

    Article  PubMed  CAS  Google Scholar 

  44. Wolff RA, Evans DB, Crane CH, et al. Initial results of preoperative gemcitabine-based chemoradiation for resectable pancreatic adenocarcinoma. Clin Oncol 2002;21:130a.

    Google Scholar 

  45. Ammori JB, Colletti LM, Zalupski MM, et al. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg 2003;7:766–772.

    Article  PubMed  Google Scholar 

  46. Phillip PA. Gemcitabine and platinum combinations in pancreatic cancer. Cancer 2002;95:908–911.

    Article  CAS  Google Scholar 

  47. Picozzi VJ, Kozarek RA, Traverso LW. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 2003;185:476–480.

    Article  PubMed  Google Scholar 

  48. Kaufman HL, Di Vito J, Horig H. Immunotherapy for pancreatic cancer: current concepts. Hematol Oncol Clin North Am 2002;16:159–197.

    Article  PubMed  Google Scholar 

  49. Laheru D, Jaffee EM. Pancreas cancer immunotherapy: science driving clinical progress. Nat Rev Cancer 2005;5:459–467.

    Article  PubMed  CAS  Google Scholar 

  50. Jaffee E, Hruban RH, Biedrzycki B, et al. Novel allogenic granulocyte-macrophage colony-stimulating-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001;19:145–156.

    PubMed  CAS  Google Scholar 

  51. Laheru D, Jaffee EM. Immunotherapy for pancreatic cancer: science driving clinical progress. Nat Rev Cancer 2005;5:459–467.

    Article  PubMed  CAS  Google Scholar 

  52. Reya T, Morrison SJ, Clarke MF, et al. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105–111.

    Article  PubMed  CAS  Google Scholar 

  53. Tempero M, Behrman J, Ben-Joséf E. Pancreatic adenocarcinoma. National comprehensive cancer network. Practice Guidelines in Oncology-v.1.2005. Available at http://www.accn.org/professionals/cms/pdf/pancreatic.pdf.

Download references

Author information

Authors and Affiliations

  1. From the Section of Gastrointestinal Surgery, Department of Surgery, The University of Michigan Medical Center, Ann Arbor, Michigan

    Erika A. Newman M.D., Diane M. Simeone M.D. & Michael W. Mulholland M.D., Ph.D.

Authors
  1. Erika A. Newman M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Diane M. Simeone M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael W. Mulholland M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael W. Mulholland M.D., Ph.D..

Rights and permissions

Reprints and permissions

About this article

Cite this article

Newman, E.A., Simeone, D.M. & Mulholland, M.W. Adjuvant treatment strategies for pancreatic cancer. J Gastrointest Surg 10, 916–926 (2006). https://doi.org/10.1016/j.gassur.2005.10.018

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1016/j.gassur.2005.10.018

Key words

Search

Navigation